The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Phase I results for CAR-T ACTR707 plus rituximab in R/R CD20+ B-cell lymphoma
An array of CAR T-cells are arriving following the success of the two approved products. Here, Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, discusses the results of the Phase I ATTCK‑20-03 trial (NCT03189836), evaluating the safety and activity of ACTR707 in combination with rituximab in CD20+ relapsed/refractory B-cell lymphoma. This combination induced complete responses in 3 out of 6 patients at the lowest dosage, with no adverse events leading to treatment discontinuation; supporting continued dose escalation. Dr Flinn also highlights the potential of this therapy in other malignancies. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
